Tissue-based biopsy is the present main tool to explore the molecular landscape of cancer,
but it also has many limits to be frequently executed, being too invasive with the risk of side …

Liquid biopsies using cell-free circulating tumor DNA (ctDNA) are being used frequently in
both research and clinical settings. ctDNA can be used to identify actionable mutations to …

Therapeutic vaccines that elicit cytotoxic T cell responses targeting tumor-specific
neoantigens hold promise for providing long-term clinical benefit to patients with cancer …

Gastroesophageal cancer dynamics and drivers of clinical responses with immune
checkpoint inhibitors (ICI) remain poorly understood. Potential synergistic activity of dual …

Purpose: Patients with small-cell lung cancer (SCLC) have an exceptionally poor prognosis,
calling for improved real-time noninvasive biomarkers of therapeutic response. Experimental …

Purpose: In the CASPIAN trial, first-line durvalumab plus platinum-etoposide (EP)
significantly improved overall survival (OS) versus EP alone in extensive-stage small cell …

Purpose: Although immunotherapy is the mainstay of therapy for advanced non–small cell
lung cancer (NSCLC), robust biomarkers of clinical response are lacking. The heterogeneity …

Background: In recent years, liquid biopsy has shown great potential for improving cancer
diagnosis and treatment. This study aimed to explore the trends and prospects in liquid …

Liquid biopsy is emerging as a pivotal tool in precision oncology, offering a noninvasive and
comprehensive approach to cancer diagnostics and management. By harnessing biofluids …

Breast cancer management has witnessed significant advancements, especially in the
diagnosis and treatment response monitoring through the implementation of imaging …